SCHEMBL23631967

SCHEMBL23631967

CC(C)(C)OC(=O)N1CC(c2ccc(C(F)(F)F)cc2)=C[C@H]1CO

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 1/20 0.42
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
TACR1 P25103 6/20 0.40
MAPT P10636 1/20 0.40
P2RY14 Q15391 1/20 0.38
GHSR Q92847 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GPR119 Q8TDV5 2/20 0.37
HSD11B1 P28845 1/20 0.36
MMP13 P45452 1/20 0.36
APP P05067 1/20 0.36
UCHL1 P09936 1/20 0.35
TGFBR1 P36897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23632067 1.00 NR1H2 (0.42) NR1H2NR1H3CYP11B1CYP11B2TACR1
SCHEMBL29035289 0.88 TACR1 (0.41) NR1H2TACR1MEN1KMT2AMMP13
SCHEMBL29035291 0.88 TACR1 (0.41) NR1H2TACR1MEN1KMT2AMMP13
SCHEMBL29035464 0.85 UCHL1 (0.46) NR1H2NR1H3TACR1MEN1KMT2A
SCHEMBL29035461 0.85 UCHL1 (0.46) NR1H2NR1H3TACR1MEN1KMT2A
SCHEMBL6185153 0.81 MAPT (0.42) NR1H2NR1H3CYP11B1CYP11B2MAPT
SCHEMBL23632405 0.81 MAPT (0.42) NR1H2NR1H3CYP11B1CYP11B2MAPT
SCHEMBL25366989 0.78 GPR119 (0.42) NR1H2NR1H3MAPTMEN1KMT2A
SCHEMBL25366993 0.78 GPR119 (0.42) NR1H2NR1H3MAPTMEN1KMT2A
SCHEMBL30571527 0.77 GPR119 (0.44) MEN1KMT2AGPR119UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113072542-B ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业股份有限公司 2024-04-05 CN disclosed
CN-112513021-B ROR gamma antagonist and application thereof in medicines 广东东阳光药业有限公司 2023-06-27 CN disclosed
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-04-20 US disclosed
EP-4089080-A1 RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-11-16 EP disclosed
WO-2021139595-A1 RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 东莞市东阳光新药研发有限公司 2021-07-15 WO disclosed
CN-113072542-A ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业有限公司 2021-07-06 CN disclosed
CN-112513021-A ROR gamma antagonist and application thereof in medicine 广东东阳光药业有限公司 2021-03-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF RORC, RORB, RORA NR1H2 5/4885NR1H3 6/4885CYP11B1 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.